We value your privacy

We use cookies to analyze site usage and improve your experience. You can accept all, reject non-essential, or customize. See our Privacy Policy.

Safety \u00b7 Long-term

HRT and cancer risk: the honest breakdown

The WHI's cancer signals were smaller and more nuanced than headlines suggested. Modern regimens (transdermal estradiol + micronized progesterone) look cleaner than the 2002 CEE+MPA arm on nearly every cancer endpoint.

Written by the Kindr Health Editorial & Clinical TeamMedically reviewed by Kindr Health Clinical Team NPI 1609792902Published Last reviewed

Key points

  • Match regimen to individual risk
  • Prefer transdermal + micronized progesterone
  • Regular mammography per guidelines

Frequently asked questions

Does HRT cause breast cancer?

Depends on regimen: estrogen-only reduced incidence in WHI. Combined with synthetic MPA modestly raised it after 5 years.

What about endometrial cancer?

Adequately protected by progesterone or IUD.

Ovarian and colon cancer?

Small ovarian signal in long-duration use; reduced colorectal incidence in the combined arm.

Considering a physician-supervised longevity protocol? Kindr Health evaluates peptide therapy as part of personalized perimenopause and menopause care.

Request your Longevity Consult →

Explore Kindr Health

HRT Hub →
Estrogen, progesterone, testosterone protocols
34 Symptoms →
The complete symptom index
Care Near Me →
Find menopause care in your city
Browse by State →
Licensed clinicians in all 50 states
Kindr Journal →
Evidence-based menopause reporting
Editorial Team →
Who reviews Kindr clinical content

Related: FDA peptide review July 2026 briefing · Peptide therapy hub · Longevity service

Written and medically reviewed by the Kindr Health Clinical Team · Published 2026-06-19 · Last reviewed 2026-07-01. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products.